1. Field of the Invention
The present invention relates to methods and apparatus for therapeutically treating connective tissue and/or increasing vascularization in tissue using ultrasound. More particularly, the present invention relates to methods and apparatus which use ultrasound to stimulate growth or healing, or to treating and/or preventing pathologies of connective tissue, or to increase vascularization in ischaemic or grafted tissue using ultrasound.
2. Description of the Related Art
The use of ultrasound to therapeutically treat and evaluate bone injuries is known. Impinging ultrasonic pulses having appropriate parameters, e.g., frequency, pulse repetition, and amplitude, for suitable periods of time and at a proper external location adjacent to a bone injury has been determined to accelerate the natural healing of, for example, bone breaks and fractures.
U.S. Pat. No. 4,530,360 to Duarte describes a basic non-invasive therapeutic technique and apparatus for applying ultrasonic pulses from an operative surface placed on the skin at a location adjacent to a bone injury. To apply the ultrasound pulses during treatment an operator must manually hold the applicator in place until the treatment is complete.
The Duarte patent as well as U.S. Pat. No. 5,520,612 to Winder et al. describe ranges of RF signal for creating the ultrasound, ultrasound power density levels, ranges of duration for each ultrasonic pulse, and ranges of ultrasonic pulse frequencies.
U.S. Pat. No. 5,003,965 to Talish et al. relates to an ultrasonic body treatment system having a body-applicator unit connected a remote control unit by sheathed fiber optic lines. The signal controlling the duration of ultrasonic pulses and the pulse repetition frequency are generated apart from the body-applicator unit. Talish et al. also describes a mounting fixture for attaching the body-applicator unit to a patient so that the operative surface is adjacent the skin location.
While the systems described in these patents relate to therapeutic methods and apparatus for ultrasonic treatment of hard and soft issue injuries and defects, there is a need for ergonomically configured signal generators and transducers for the treatment of cartilage and/or osteochondral injuries and/or defects and/or for the treatment of cartilage/degenerative joint diseases, such as osteoarthritis (OA). Further, a need exists for an apparatus which optimizes the treatment of cartilage and/or osteochondral injuries and/or defects and/or the treatment of cartilage/degenerative joint diseases, such as osteoarthritis.
A cartilage and/or osteochondral injury and/or defect and/or degenerative joint disease, such as osteoarthritis, typically involves damage to the cartilage which lines articulating bones (articular cartilage), such as the bones of the knee, elbow, shoulder and ankle. Osteochondral injuries can be treated by chondral and/or osteochondral drilling causing blood flow at the site. The aim of chondral drilling is to stimulate cartilage regeneration as part of the healing process. However, the resulting nonhyaline or fibrocartilage produced is biomechanically inferior to articular cartilage, does not have comparable proteoglycan content, and may consist primarily of a thin unorganized layer of collagen. Further, it has been observed that degeneration of the new tissue generally occurs over time, requiring the need for additional reconstructive surgical treatment.
Other methods of treatment include: the transplantation of non-weight bearing cartilage to the injury and/or defect site; inducing a fracture at the injury and/or defect site; placing a carbon fiber matrix to induce cartilage formation; and autologous chondrocyte implantation (ACI). ACI entails removing chondrocytes capable of regenerating hyaline-like cartilage from the body and culturing them for several weeks. During the culture process, the number of cells increases approximately 15 times that of the original tissue sample. The cultured cells are then transplanted through an arthrotomy. A small piece of periosteum, the skin covering a bone, is taken from the patient's tibia. The periosteum is then sutured over the defect to provide a protective cover for the cultured cells. The cultured cells are injected under the periosteum into the defect where they will continue to multiply and produce a durable repair tissue. However, ACI increases the healing time since the chondrocytes need to be cultured before they are transplanted to the patient.
Therefore, there is a further need for a method and apparatus to stimulate cartilage regeneration which produces a repair tissue that is fibrocartilage or hyaline-like, and which is equivalent to articular cartilage in mechanical properties. There is also a need for repair tissue that is generally superior in mechanical properties to that generated using conventional techniques, as described above. Further still, a need also exists for an apparatus which stimulates cartilage regeneration and where the regenerated cartilage does not degenerate over time requiring additional treatment or reconstructive surgery. Further, there is a need for an apparatus which stimulates cartilage regeneration and significantly reduces the healing time.
For treatment of degenerative joint diseases such as osteoarthritis, some combination of symptom-modifying drug, physiotherapy with nonsteroidal antiinflammatories (NSAID's), bracing, weight loss, and/or reduced activity are initially used. However, while these approaches may control symptoms, they do not effectively address the underlying damage to connective tissue, such as cartilage. Moreover, the drugs used may cause severe side effects in some patients, which can result in hospitalization and, in some cases, death. It has been reported that an estimated 20,000 OA patients die each year in the United States from gastrointestinal complications associated with NSAID use. If symptoms remain after these treatments, then more invasive treatment methods are often used, such as injection of viscoelastic materials, arthroscopic surgery, or total joint replacement. There remains a need for additional methods and apparatus that treat and repair connective tissue damage, e.g. damage to cartilage, rather than simply control symptoms of osteoarthritis, and that do not have the side effects and/or tolerance problems associated with current pharmaceutical therapies.
However, injuries and pathologies of cartilage are not the only conditions of connective tissue requiring treatment that involve significant healing time. When ligament and tendons rupture the patients have pain and laxity of the joint or muscle. The current repair options available to the surgeon are to replace or reconstruct the damaged tissue with autograft or allograft tissue, augmentation of the tear surfaces with a device, or by fixation of the tissue with devices such as sutures or anchors, or to simply treat symptoms such as pain and inflammation, without resolving the underlying problem. Because of the risks associated with surgery, treatment options that do not necessarily involve surgery would be desirable. In addition, the repaired tissue is often not as strong as the original undamaged tissue, so that methods to increase repair tissue strength and decrease rehabilitation time would also be desirable. The success of therapies involving replacement or reconstructed tissue is often dependent on the body's ability to vascularize the tissue. Increased vascularization will lead to improved, faster healing, while insufficient vascularization can lead to necrosis of the tissue. Thus, methods for increasing vascularization in surgically repaired tissues would be advantageous.
In addition, in allograft or autograft replacement, the graft dies off and is subsequently repopulated and remodeled by infiltrating cells. This is a lengthy process during which time the graft loses strength and is at risk of rerupture or damage. This leads to lengthy rehabilitation times (e.g., a minimum of 6 months for anterior cruciate ligament (ACL) reconstruction). Inhibiting cell death within the graft via stimulation of blood vessel and tissue in-growth would therefore be desirable. This will lead to a faster and stronger repair and reduced rehabilitation time thus the patients will return to full function faster. The phenomenon of “bone tunnel widening” can often present a problem. Improved integration of bone/tissue/ligament interfaces would help to avoid the “windshield wiper effect” posited as a mechanism for bone tunnel widening.
Surgical methods are also typically required to repair menisci in the knee, for example. Increased vascularization of the avascular “white zone” of the menisci is desirable due to the stimulation in healing that results.
As explained above, the current treatments for many or most of these connective tissue injuries/pathologies are either surgical procedures including repair, reconstruction, augmentation, fixation and tissue resection, or the use of drug therapies that reduce the pain and inflammation. These procedures are usually followed by (or combined with) rehabilitation including physiotherapy which will include a series of stretching exercises with a gradual increase in range of motion and loading on the repair tissue. However, physiotherapy is inconvenient, time consuming and relatively expensive, which can lead to problems with patient compliance. There is thus a need in the art for methods of speeding healing and increasing vascularization that lend themselves to use by the patient at home, and do not require a significant amount of time each day.
It is often desirable to address problems such as laxity of joints by modifying tissues such that the collagenous components of connective tissues (joint capsules, tendons, ligaments) are induced to contract, a procedure often termed capsulorraphy. Applying thermal energy to collagen can cause an alteration of the molecular configuration resulting in shrinkage. This results in a shorter structure and a ‘tighter’ joint. However, the thermal energy incidentally may also damage the tissue resulting in loss of viability of cells, loss of blood supply and reduced mechanical integrity of the structure. Tissue shrinkage procedures have thus had difficulties resulting from decreased biomechanical integrity and long rehabilitation times due to slow healing. This has resulted in the ‘modified’ tissue being stretched back out prior to its healing and reestablishment of normal biomechanical strength, resulting in the loss of the benefit of the shrinkage procedure. This damage represents a significant disadvantage and has inhibited the use of capsulorraphy and related tissue shrinkage procedures. Faster post-shrinkage repair of tissue would minimize these difficulties and make the technique more widely applicable.
Tissue engineering involves the growth of cells on a scaffold in vitro (outside the body) to produce a graft for the repair of tissues within the body. One of the shortcomings of this approach is that it is not possible to grow a tissue-engineered material (implant, graft or organ) with a vascular supply in vitro. When the tissue-engineered material is placed into the body and stimulated with ultrasound functional blood vessels are stimulated to grow into the tissue-engineered material from the hosts own blood supply. This is a means of vascularization of this implanted material thus retaining the function and viability of the grafted material. There remains a need for methods and apparatus to achieve this vascularization of tissue engineered material.
The method and apparatus of the invention resolve many of the difficulties associated with conventional therapies described above. In one embodiment, the invention relates to a method for stimulating growth or healing, or treating pathologies, of connective tissue in mammals in need thereof, by subjecting the affected connective tissue to noninvasive, low intensity ultrasound of a frequency and duration sufficient to stimulate growth, healing, or repair of the connective tissue.
In another embodiment, the invention relates to a method for increasing vascularization in ischaemic or grafted tissue (not limited to connective tissue) in mammals in need thereof, by subjecting the affected tissue to noninvasive, low intensity ultrasound of a frequency and duration sufficient to stimulate an increase in vascularization in the ischaemic or grafted tissue.
In another embodiment, the invention relates to an apparatus for effecting the treatment method described herein. The apparatus includes a placement module adapted to secure one or more transducers thereto in a plurality of configurations. The placement module is then secured to a site near the tissue in need of treatment, for example, at the knee, hip, ankle, shoulder, elbow, or wrist, and the transducers actuated to emit ultrasound sufficient to stimulate healing or repair, or to increase vascularization. Further, the present invention also provides an embodiment having a placement module which contains a locking structure for locking in a particular position the articulating bones of a joint undergoing treatment. This embodiment prevents the patient from moving his limbs, for example, moving the femur with respect to the tibia, during treatment.
In another embodiment, the invention relates to an apparatus for positioning one or more ultrasonic transducers with respect to a joint for delivery of ultrasonic therapy thereto, having a covering member adapted to cover at least a portion of the joint or adjacent body members and be secured thereto in a fixed position, wherein the covering member comprises one more receiving areas adapted to receive and hold one or more ultrasonic transducer assemblies in one or more fixed positions relative to the joint or adjacent body member.
Because of the broad applicability of utility of the invention in promoting healing, the method and apparatus described herein are useful in treating patients with a broad range of problems, such as trauma, tissue insufficiency, pain, post-surgical healing, degenerative conditions such as osteoarthritis, and other problems. Moreover, because the invention is portable, does not require prolonged treatment times, and is designed for ease of use and positioning of the ultrasonic transducers, patients will be more likely to use the technique properly and sufficiently to benefit therefrom.
Specific embodiments of the invention are descried below with reference to the drawings, which are described as follows:
The ultrasonic treatment apparatus and method of the present invention involves the non-invasive use of low intensity, ultra high-frequency acoustic energy (ultrasound) to treat injuries, defects, or pathologies of connective tissue, or to increase vascularization of ischaemic or grafted tissue. It will be recognized that in treating connective tissue, increased vascularization will likely result and contribute to healing, but that the use of the method and apparatus to increase vascularization is not limited to treatment of connective tissue, but extends to grafted tissues, organs, or engineered tissue that has been produced ex vivo.
As described above, in one embodiment, the invention relates to an apparatus and method for the treatment of injuries and pathologies, and the stimulation of healing, of connective tissues. The method may be used as an adjunct to surgical repair, in order to speed healing, or in some cases can be used alone to heal tissue injuries without surgery (e.g., for degenerative diseases such as osteoarthritis, tendonosis, and tendonitis). The apparatus and method of the invention are particularly suitable for use in treatment of connective tissues associated with joints, such as those in the hand or foot, wrist, ankle (Achilles tendon), knee (e.g., anterior cruciate ligament, posterior cruciate ligament, meniscofemoral ligament, lateral or collateral ligaments, tendon of quadriceps, gracilis tendon, sartorius tendon, semitendinosis to tendon, popliteus tendon, adductor magnus tendon, medial or lateral meniscus), elbow (lateral, collateral, or annular ligaments), hip, shoulder (e.g., supraspinatus tendon/rotator cuff/glenoidal labrum), back and neck.
Nonlimiting examples of conditions or situations in which treatment according to the invention is suitable include degenerative diseases such as osteoarthritis, ligament, tendon, spinal disc and meniscus injuries, ligament and tendon pathologies, surgical repair or modification (including modification procedures such as capsulorraphy (shrinkage), and procedures for shrinkage of the spinal disc (for example the Idet procedure), and for the treatment of ischaemic tissues (such as a myocardially infarcted heart) to increase vascularization by inducing a vascular supply (in-growth of new blood vessels) into these tissues (used herein to refer to tissues that have either a restricted blood flow or a lack of adequate vascular supply). The invention could also be used to increase vascularization in a grafted tissue/organ or into a tissue engineered graft that has been produced ex vivo.
The invention can be used as an adjunct to the surgical repair of ruptured ligament and tendons (for example rotator cuff tendon repair, anterior cruciate ligament, posterior cruciate, lateral collateral ligament, medial collateral, flexor or extensor repairs, Achilles tendon, surgical tendon transfers or tendon weaves).
The invention is suitable for treatment of a number of different tendoniopathies and/or overuse injuries, including without limitation lateral or medial epicondylitis (tennis elbow), carpal tunnel syndrome, plantar fascitis, Achilles tendonitis, and the like, as either an adjunct to surgery, or without surgery.
The invention can also be used to increase the rate, quality and vascularity of connective tissue that is regenerated on, and/or grows into, a scaffold which is implanted into the body to support connective repair/regrowth. The term “scaffold” as used herein means a three dimensional, at least partially porous structure, and having sufficient porosity to allow cell infiltration. The scaffold surface allows cell adhesion and growth such that cell proliferation and extracellular matrix (ECM) generation can occur and tissue can be laid down and remodel.
The scaffolds can be formed from bioresorbable or non-bioresorbable materials. Suitable bioresorbable materials include bioresorbable polymers or copolymers including, for example, polymers and/or copolymers formed from the following monomers or mixtures thereof: hydroxy acids, particularly lactic acid, glycolic acid; caprolactone; hydroxybutyrate; dioxanone; orthoesters; orthocarbonates; and/or aminocarbonates. The bioresorbable materials may also contain natural materials such as collagen, cellulose, fibrin, hyaluronic acid, fibronectin, chitosan or mixtures of two or more of these materials. The bioresorbable materials may also contain devitalised xenograft and/or devitalised allograft material. Bioresorbable ceramics, such mono-, di-, octa-, a-tri-, b-tri and tetra-calcium phosphate, hydroxyapatite, fluoroapatite, calcium sulphate, calcium fluoride, calcium oxide or mixtures of two or more of these materials, may also be used as scaffold material.
Suitable non-bioresorbable materials for use in scaffolds include polyesters, particularly aromatic polyesters, such as polyalkylene terephthalates, like polyethylene terephthalate and polybutylene terephthalates; polyamides; polyalkenes such as polyethylene and polypropylene; poly(vinyl fluoride), polytetrafluoroethylene carbon fibres, silk (natural or synthetic), carbon fibre, glass and mixtures of these materials.
Scaffolds may also be formed from materials that include hydrogels. Examples of suitable hydrogel materials include: poly(oxyethylene)-poly(oxypropylene) block copolymers of ethylene diamine, polysaccharides, chitosan, poly(vinyl amines), poly(vinyl pyridine), poly(vinyl imidazole), polyethylenimine, poly-L-lysine, growth factor binding or cell adhesion molecule binding derivatives, derivatised versions of the above, e.g. polyanions, polycations, peptides, polysaccharides, lipids, nucleic acids or blends, block-copolymers or combinations of the above or copolymers of the corresponding monomers; agarose, methylcellulose, hydroxypropylmethylcellulose, xyloglucan, acetan, carrageenan, xanthan gum/locust bean gum, gelatine, collagen (particularly Type 1), PLURONICS™, POLOXAMERS™, poly (N-isopropylacrylamide) and N-isopropylacrylamide copolymers.
Structurally, the scaffold may be a woven, non-woven (fibrous material), knitted, braided or crocheted material, a foam, a sponge, a dendritic material, or a combination or mixture of two or more of these.
Following surgery, the ultrasound device is applied non-invasively to the outside of the body (e.g., coupled to the skin with coupling media, such as a gel) after surgery in the region of the repaired tissue, and is operated to transmit ultrasound, desirably in the form of pulses, into the tissue in need of treatment, or at the interface with the uninjured tissues. Exposure to the ultrasound stimulates a faster, better quality repair of the tissue. At a bone interface, the ultrasound will also stimulate bone repair and bone in growth into the repair or graft tissue. This gives rise to a faster, stronger repair and improved integration of the interface between, e.g., tendon, ligament and bone.
The method and apparatus of the invention may also be used to non-invasively treat pathologies of connective tissues, such as osteoarthritis, ligament and tendon conditions, without the need for a surgical procedure. Such conditions include, as examples, osteoarthritis, acute tears, chronic overuse injuries, and tendon pathologies including tendonosis and tendonitis. In these cases the device would be applied to the skin in the region of pain above the injured or degenerative tendon or ligament. The ultrasound would then propagate in to the defective tissue and stimulate the tissue to remodel and repair without the requirement for surgery. The treatment thus would improve the in-vivo function of the tissue with respect to mechanical load bearing, and avoid the risks and disadvantages associated with surgery, as described above.
As described above, the method and apparatus of the invention is also particularly suitable for stimulating repair of damaged menisci. This could be done after surgical repair to stimulate the healing process, or as a possible alternative to surgery. Without being bound by any theory, the invention appears to be particularly useful because it stimulates healing of the avascular ‘white zone’ of the meniscus by stimulating in-growth of blood vessels and their concomitant cell populations, which are capable of healing the damaged tissue. More particularly, the meniscal cartilage is partially vascularized in the external periphery of the tissue and has an avascular inner region. If the vascular region is damaged, it usually heals or can be repaired due to the presence of a blood supply. If the avascular region is damaged, it does not heal and cannot be easily repaired because of the absence of blood supply. As a result, damaged avascular regions often must be resected, which can lead to post meniscectomy arthritis. However, using the method and apparatus of the invention repair of the avascular region becomes possible due to the ability of the invention to stimulate vascularization.
However, the method and apparatus of the invention is not limited to increasing vascularization of damaged menisci, but can also be used to treat general ischaemic tissues which have restricted blood flow and/or a lack of adequate vascular supply. For instance, the method and apparatus of the invention can be used to induce a vascular supply and in growth into a grafted tissue or organ, or into a tissue engineered graft that has been produced ex vivo and pro lacks a vascular supply. The invention could also be used to treat tissues with a partial vascular supply to stimulate repair of tissues in the avascular region of the tissue.
In addition to surgical and nonsurgical treatment of tissue injuries, defects, or pathologies, the method and apparatus of the invention can also be used as an adjunct to tissue modification treatments, such as capsulorraphy, or shrinkage of the spinal disc and related or similar tissue shrinkage procedures, to significantly increase the success rate and benefit to the patient of undergoing such procedures. As described above, the use of thermal energy to alter the configuration of connective tissue and thereby eliminate joint laxity is associated with problems relating to tissue damage. Loss of cell viability, loss of blood supply, and reduced mechanical integrity can result in loss of many of the benefits associated with the tissue shrinkage procedure.
The method and apparatus of the invention provides a means to address these potentially adverse effects by stimulating revascularization and cell repopulation, resulting in repair and return to normal biomechanical integrity. The invention adds to the ability to shrink the tissue the ability to also rapidly heal it in its shortened configuration, and as a result offers a new treatment option that was previously difficult to achieve. This invention thus makes practical a new treatment method having the significant benefits associated with a reduced surgical procedure, i.e. a less invasive and traumatic procedure, for otherwise difficult to treat cases. The reduction in healing time obtainable with the method and apparatus of the invention means that that the chances of the weakened tissue being stretched are reduced. The reduction in rehabilitation time allows the patient to return to normal activities more quickly. The combination of a minimally invasive procedure using radiofrequency tissue shrinkage technology in combination with the method and apparatus of the invention provides a procedure offering dramatically reduced rehabilitation time and an opportunity to treat a broader range of patients and disorders without surgery.
The method and apparatus of the invention can be combined with pharmacological treatment modes, and these combinations also form a part of the invention. For instance, the method of the invention can be used in conjunction with known growth factor therapies, including but not limited to, the Transforming Growth Factor β superfamily, including: TGFβ's, Bone Morphogenetic Proteins (BMP's, e.g. BMP2, BMP4), Cartilage Derived Morphogenic Proteins (CDMP's e.g. CDMP-1, CDMP-2) and Growth Differentiation Factors (e.g. GDF5), angiogenic factors (angiogenin), platelet-derived cell growth factor (PD-ECGF), Platelet Derived Growth Factors (PDGF), Vascular Endothelial Growth Factor (VEGF), the Epidermal Growth Factor family, e.g. EGF, Transforming Growth Factor Alpha (TGFα), Platelet Derived Growth Factors, e.g. PDGF-A, PDGF-B, PDGF-BB, Fibroblast Growth Factors, e.g. BFGF, Hepatocyte Growth Factors (HGF), Insulin-like Growth Factors, e.g. IGF-1, IGF-II, Growth Hormones (GH), Interleukins (e.g. IL-1, IL-11), Connective Tissue Growth Factors (CTGF), Parathyroid Hormone Related Proteins (PTHrp), autologous growth factors (such blood and platelet derived factors), and mixtures of at least two of these materials. In conjunction with growth factor therapies, the method and apparatus of the invention provide a faster, better quality repair. Appropriate dosages of such growth factors are those known in the art for use in therapy without ultrasound treatment.
As described in more detail below, the apparatus of the invention contains one or more ultrasound treatment heads that direct ultrasonic energy to the site of the tissue to be treated through the overlying tissues. Without being bound by any theory, it is believed that the ultrasonic energy provides a mechanical stimulus that induces tissue repair and also stimulates blood vessel in growth and blood flow to the tissue which aids the healing or repair process. This stimulation appears to be the result of a molecular mechanism related to vascularity through an increase in growth factor and biological molecules known to be vital for angiogenesis, matrix production and cellular proliferation. The pathway may be mediated through signal transduction molecules that regulate cellular function.
The ultrasound is generally a low intensity ultrasound having a frequency ranging between about 1 and about 2 MHz, more particularly about 1.5 MHz. The ultrasound desirably is pulsed, having a pulse width ranging from about 10 to about 2,000 microseconds, more particularly about 200 microseconds, with a repetition frequency ranging from about 0.1 to about 10 KHz, more particularly about 1 KHz.
The ultrasonic energy is emitted by one or more transducers. Multiple transducers are often desirable, in particular for treating some types of ligament injury, and when present can be configured into arrays to properly place them adjacent to areas to be treated. For example ACL surgical repairs can be treated with multiple transducers, each in a separate treatment head. One treatment head is applied to the outside of the knee in the region of the tibial bone tunnel; another treatment head is applied to knee in the region of the mid section of the graft and another treatment head is applied to knee in the region of the femoral bone tunnel. Multiple transducers can also be set to emit energy simultaneously (e.g., in simultaneous pulses) or in a phased fashion, such that they emit pulses sequentially.
One embodiment of the apparatus of the invention includes an ergonomically constructed placement module having a strap or other fastening means for securing it and the attached transducer or treatment head adjacent to the part of a patient's body in need of treatment. At least one ultrasonic transducer assembly is attached or imbedded within the placement module and properly positioned on the various anatomical regions in proximity to the desired treatment site. Different types of ultrasonic transducers and signals can be provided, such as those described and schematically depicted in U.S. Pat. No. 5,520,612 to Winder et al., which is incorporated herein by reference. The transducers described in U.S. Pat. No. 5,520,612 produce ultrasound having an intensity less than 100 milliwatts/cm2. Particularly, the transducers and arrangements schematically depicted by
Turning to the figures, in particular
The placement module 14 comprises a placement support 20 which includes at least two or three channels 22 each having an extension 24 mounted therein. Each extension has a transducer pocket 26 at one end or holding one ultrasonic transducer assembly 16. It is contemplated for each extension 24 to have several range of movements besides longitudinal motion, such as articulating to the longitudinal motion.
The placement module 14 further includes a placement band 28 cooperating with slot 30 for securing the placement support 20 to the patient. The placement band 28 is configured to firmly secure the placement module 14 to the patient. A sponge-like material 32 can be used to line the inner surface of the placement support 20 for providing comfort to the patient (
With reference to
The transducer assembly 16 may include circuitry, schematically illustrated by
In operation, the placement module 14 is positioned and secured to the patient's body as shown by
It is also contemplated that one or more transducers can be converted to receive reflected diagnostic data from the treatment site. This permits real time evaluation of the injury site and healing process.
With reference to
A second embodiment of the portable ultrasonic treatment apparatus of the present invention is illustrated by
It is envisioned that the placement module 204b constructed from suitable conductive plastics, such as conductive ABS plastics with either carbon, stainless steel, nickel or aluminum fibers to forego the use of wires for connecting the transducer assemblies 202 to the cable 218. In such an embodiment, the conductive placement module 204 would be used to electrically connect the transducer assemblies 202 to the MOU 12 via cable 218.
With reference to
In operation, transducers within transducer assemblies 306 are excited for a predetermined period of time to impinge ultrasonic waves to articular cartilage within the shoulder region.
A fourth embodiment of the portable ultrasonic treatment apparatus of the present invention which is primarily suitable for the treatment of connective tissue is illustrated by
In operation, at least one transducer assembly 402 is excited to impinge ultrasonic waves to the treatment site as shown by
It is also contemplated to manufacture the strip 406 from suitable conductive plastics such as conductive, ABS plastics with either carbon, stainless steel, nickel or aluminum fibers to forego the use of wires for electrically connecting the at least one ultrasonic transducer 402 to the cable 408.
A fifth embodiment of the portable ultrasonic treatment apparatus of the present invention which is primarily suitable for the treatment of connective tissue is illustrated by
As shown by the exploded view of
The thigh support 512 and the leg support 514 are locked to each other by locking the horizontal locking extensions 520 and the vertical locking extensions 530 by screws 538 and thumb screws 540 to prevent the patient from moving the thigh with respect to the leg during treatment and to ensure that the transducer assemblies 502 remain fixed in their proper positions. The transducer assemblies 502 are connected via a cable 542 which is plugged in to hole 544 to the MOU 12 which contains circuitry for exciting the ultrasonic transducer assemblies 502. It is contemplated that during treatment an ultrasonic conducting gel is positioned between the transducers 502 mounted in concave plate 506 and the patient's body to prevent attenuation of the ultrasonic waves.
Alternative embodiments of the placement module described above also form a part of the invention, and are illustrated in
An ovine model of soft tissue graft (digital extensor tendon) reconstruction of the ACL was utilized to allow for assessment of the method and apparatus of the invention. A modified ACL reconstruction was performed on 21 animals in three groups of 7 animals. Control groups of 2 animals (provided with no ultrasound treatment), and experimental groups of 5 animals (provided with ultrasound treatment for 20 minutes continuously each day) were harvested at the end of 3, 6, and 12 weeks.
The right hind limb was operated on in all animals. The anterior cruciate ligament (ACL) was visualized and removed at the insertion site through an antero-medial arthrotomy. The ACL reconstruction was performed using a digital extensor tendon graft. The tendon graft was harvested from the same limb by 2 stab incisions. The graft was whip stitched using # 2 Ethibond and prepared using the Acufex Graftmaster. The graft was doubled and passed through 4.5 mm tunnels in the tibia and femur. Endobutton fixation was used on the femoral side with tibial fixation over a bony post. The surgical incisions were then closed using standard suturing techniques. The animals were then recovered and ultrasound treatment was initiated on the members of the experimental group one day following surgery.
The animals in the treatment groups were treated with pulsed low intensity ultrasound (1.5 MHz, pulsed at 1 KHz, 200 μs burst width) for 20 minutes per day for the duration of the study. Ultrasound devices having two ultrasound transducers were used. One transducer was coupled to the skin (wool was shaved) over the femoral bone tunnel containing the graft, while the other was coupled to the skin over the tibial attachment tunnel. The transducers were held in place during treatment with strapping.
Animals were sacrificed at 3, 6 and 12 weeks following surgery with an intravenous lethal injection of anesthetic. The right hind limb of each was stripped of soft tissue and muscle and fixed in 10% phosphate buffered formalin for a minimum of 72 hours with changes every 24 hours. The femoral and tibial bone tunnels were isolated using a saw and decalcified in 10% formic acid—formalin solution. The femur and tibial tunnels were sectioned into 2-3 mm slices from the joint space to the outer cortex and placed into cassettes for paraffin embedding. Five-micron thick sections were cut on a microtome and stained with hematoxylin and eosin for microscopic analysis.
After 3 weeks of ultrasound treatment there are marked differences visible between histology images of tissue from the control animals (
After 6 weeks of ultrasound there is extensive neoangiogenesis in the graft, as shown in
At 12 weeks, the intra-articular section of the graft in the control group, shown in
Hartley strain guinea pigs that spontaneously develop osteoarthritis (OA) were used for this study. This strain develops an arthropathology that mimics human OA between the age of 6 and 12 months of age. The OA is confined to the medial tibia plateau in the early stages of the disease.
Eight animals were utilized for this study. The animals were 2 months of age when the study was initiated. The left legs of the animals were treated with pulsed low intensity ultrasound (1.5 MHz, pulsed at 1 KHz, 200 μs burst width) for a period of 4 months. The ultrasound was applied for 20 minutes per day, for 5 days per week. The ultrasound transducer was coupled to the skin with gel on the media side of the left knee after first shaving the knee joint. The transducers were held in place during treatment with strapping. The animals were terminated at 6 months of age after 4 months of treatment.
The ultrasound treated (
It will be understood that various modifications can be made to the various embodiments of the present invention herein disclosed without departing from its spirit and scope. For example, various modifications may be made in the structural configuration of the placement modules and the configuration of the components used to excite the ultrasonic transducer. Therefore the above description should not be construed as limiting the invention by merely as presenting preferred embodiments of the invention. Those skilled in the art will envision other modifications within the scope and spirit of the present invention as defined by the claims presented below.
This application is a continuation-in-part of, and claims priority to, U.S. Ser. No. 10/096,216, filed Mar. 11, 2002, now abandoned, which is a continuation of Ser. No. 09/436,999, filed Nov. 9, 1999, now U.S. Pat. No. 6,355,006, which is a continuation of International Application PCT/US98/02447, filed Feb. 6, 1998, which claims priority to U.S. Provisional Application No. 60/037,367 filed on Feb. 6, 1997. This application is a continuation-in-part of, and claims priority to, U.S. Ser. No. 09/568,481 filed May 9, 2000, now U.S. Pat. No. 6,432,070, which claims priority to U.S. Provisional Application No. 60/133,442, filed May 11, 1999, the entire contents of each of which are incorporated herein by reference.
Number | Name | Date | Kind |
---|---|---|---|
1063782 | Dickey et al. | Jun 1913 | A |
1604870 | Asman | Oct 1926 | A |
2914829 | Willemain | Dec 1959 | A |
2920853 | Bufogle | Jan 1960 | A |
3117571 | Fry et al. | Jan 1964 | A |
3134451 | Hanssen | May 1964 | A |
3193034 | Hutchinson et al. | Jul 1965 | A |
3241375 | Canzoneri | Mar 1966 | A |
3304036 | Davis | Feb 1967 | A |
3310049 | Clynes | Mar 1967 | A |
3433663 | Underwood | Mar 1969 | A |
3499437 | Balamuth | Mar 1970 | A |
3521225 | Kursman et al. | Jul 1970 | A |
3550586 | Balamuth | Dec 1970 | A |
3575050 | Lynnworth | Apr 1971 | A |
3575060 | Lynnworth | Apr 1971 | A |
3594993 | Heyse | Jul 1971 | A |
3664626 | Sneller | May 1972 | A |
3701352 | Bosworth | Oct 1972 | A |
3714619 | Morgan et al. | Jan 1973 | A |
3729162 | Salvato | Apr 1973 | A |
3760799 | Crowson | Sep 1973 | A |
3767195 | Dimick | Oct 1973 | A |
3828769 | Mettler | Aug 1974 | A |
3855638 | Pilliar | Dec 1974 | A |
3890953 | Kraus et al. | Jun 1975 | A |
3961380 | Garr | Jun 1976 | A |
3986212 | Sauer | Oct 1976 | A |
4037592 | Kronner | Jul 1977 | A |
4105017 | Ryaby et al. | Aug 1978 | A |
4108165 | Kopp et al. | Aug 1978 | A |
4127125 | Takemoto et al. | Nov 1978 | A |
4141524 | Corvese, Jr. | Feb 1979 | A |
4164794 | Spector et al. | Aug 1979 | A |
4170045 | Estes | Oct 1979 | A |
4176664 | Talish | Dec 1979 | A |
4195517 | Kalinoski et al. | Apr 1980 | A |
4206516 | Pilliar | Jun 1980 | A |
4216766 | Duykers et al. | Aug 1980 | A |
4227111 | Cross et al. | Oct 1980 | A |
4229992 | McKee et al. | Oct 1980 | A |
4233477 | Rice et al. | Nov 1980 | A |
4266532 | Ryaby et al. | May 1981 | A |
4266533 | Ryaby et al. | May 1981 | A |
4269797 | Mikiya et al. | May 1981 | A |
4291025 | Pellico | Sep 1981 | A |
4296753 | Goudin | Oct 1981 | A |
4312536 | Lloyd | Jan 1982 | A |
4315503 | Ryaby et al. | Feb 1982 | A |
4315514 | Drewes et al. | Feb 1982 | A |
4347645 | Iseki | Sep 1982 | A |
4351069 | Ballintyn et al. | Sep 1982 | A |
4355428 | Deloison et al. | Oct 1982 | A |
4358105 | Sweeney, Jr. | Nov 1982 | A |
4361154 | Pratt, Jr. | Nov 1982 | A |
4365359 | Raab | Dec 1982 | A |
4383533 | Bhagat et al. | May 1983 | A |
4407044 | Iseki | Oct 1983 | A |
4410158 | Maffei | Oct 1983 | A |
4421119 | Pratt, Jr. | Dec 1983 | A |
4431038 | Rome | Feb 1984 | A |
4440025 | Hayakawa et al. | Apr 1984 | A |
4441486 | Pounds | Apr 1984 | A |
4446586 | Reed et al. | May 1984 | A |
4452326 | Hanssen et al. | Jun 1984 | A |
4467659 | Baumoel | Aug 1984 | A |
4476874 | Taenzer et al. | Oct 1984 | A |
4482942 | Blaisdell et al. | Nov 1984 | A |
4511921 | Harlan et al. | Apr 1985 | A |
4530360 | Duarte | Jul 1985 | A |
4536894 | Galante et al. | Aug 1985 | A |
4542539 | Rowe, Jr. et al. | Sep 1985 | A |
4542744 | Barnes et al. | Sep 1985 | A |
4550714 | Talish et al. | Nov 1985 | A |
4556066 | Semrow | Dec 1985 | A |
4557148 | Akiyama | Dec 1985 | A |
4570487 | Gruber | Feb 1986 | A |
4570640 | Barsa | Feb 1986 | A |
4570927 | Petrofsky et al. | Feb 1986 | A |
4573996 | Kwiatek et al. | Mar 1986 | A |
4594662 | Devaney | Jun 1986 | A |
4603146 | Kligman | Jul 1986 | A |
4612160 | Donlevy et al. | Sep 1986 | A |
4627429 | Tsuk | Dec 1986 | A |
4630323 | Sage et al. | Dec 1986 | A |
4644942 | Sump | Feb 1987 | A |
4646725 | Moasser | Mar 1987 | A |
4657543 | Langer et al. | Apr 1987 | A |
4669483 | Hepp et al. | Jun 1987 | A |
4677438 | Michiguchi et al. | Jun 1987 | A |
4680967 | Rost | Jul 1987 | A |
4687195 | Potts | Aug 1987 | A |
4689986 | Carson et al. | Sep 1987 | A |
4708127 | Abdelghani | Nov 1987 | A |
4710655 | Masaki | Dec 1987 | A |
4725272 | Gale | Feb 1988 | A |
4726099 | Card et al. | Feb 1988 | A |
4763661 | Sommer et al. | Aug 1988 | A |
4770184 | Greene, Jr. et al. | Sep 1988 | A |
4774959 | Palmer et al. | Oct 1988 | A |
RE32782 | Pratt, Jr. | Nov 1988 | E |
4782822 | Ricken | Nov 1988 | A |
4787070 | Suzuki et al. | Nov 1988 | A |
4787888 | Fox | Nov 1988 | A |
4792336 | Hlavacek et al. | Dec 1988 | A |
4802477 | Gabbay | Feb 1989 | A |
4830015 | Okazaki | May 1989 | A |
4836316 | Carnevale et al. | Jun 1989 | A |
4855911 | Lele et al. | Aug 1989 | A |
4858599 | Halpern | Aug 1989 | A |
4867169 | Machida et al. | Sep 1989 | A |
4877805 | Kligman | Oct 1989 | A |
4891849 | Robinson | Jan 1990 | A |
4905671 | Senge et al. | Mar 1990 | A |
4913157 | Pratt, Jr. et al. | Apr 1990 | A |
4917092 | Todd et al. | Apr 1990 | A |
4917376 | Lo | Apr 1990 | A |
4920966 | Hon et al. | May 1990 | A |
4926870 | Brandenburger | May 1990 | A |
4928959 | Bassett et al. | May 1990 | A |
4930358 | Motegi et al. | Jun 1990 | A |
4932951 | Liboff et al. | Jun 1990 | A |
4933230 | Card et al. | Jun 1990 | A |
4936303 | Detwiler et al. | Jun 1990 | A |
4941474 | Pratt, Jr. | Jul 1990 | A |
4947853 | Hon | Aug 1990 | A |
4979501 | Valchanov et al. | Dec 1990 | A |
4982730 | Lewis, Jr. | Jan 1991 | A |
4984462 | Hass, Jr. et al. | Jan 1991 | A |
4986275 | Ishida et al. | Jan 1991 | A |
4993413 | McLeod et al. | Feb 1991 | A |
4995883 | Demane et al. | Feb 1991 | A |
5000183 | Bonnefous | Mar 1991 | A |
5000442 | Dalebout et al. | Mar 1991 | A |
5003965 | Talish et al. | Apr 1991 | A |
5004476 | Cook | Apr 1991 | A |
5016641 | Schwartz | May 1991 | A |
5018285 | Zolman et al. | May 1991 | A |
5046484 | Bassett et al. | Sep 1991 | A |
5054490 | Rossman et al. | Oct 1991 | A |
5067940 | Liboff et al. | Nov 1991 | A |
5080672 | Bellis | Jan 1992 | A |
5088976 | Liboff et al. | Feb 1992 | A |
5099702 | French | Mar 1992 | A |
5100373 | Liboff et al. | Mar 1992 | A |
5103806 | McLeod et al. | Apr 1992 | A |
5106361 | Liboff et al. | Apr 1992 | A |
5107853 | Plyter | Apr 1992 | A |
5108452 | Fallin | Apr 1992 | A |
5133420 | Smith | Jul 1992 | A |
5134999 | Osipov | Aug 1992 | A |
5139498 | Astudillo Ley | Aug 1992 | A |
5140988 | Stouffer et al. | Aug 1992 | A |
5143069 | Kwon et al. | Sep 1992 | A |
5143073 | Dory | Sep 1992 | A |
5154189 | Oberlander | Oct 1992 | A |
5163598 | Peters et al. | Nov 1992 | A |
5172692 | Kulow et al. | Dec 1992 | A |
5178134 | Vago | Jan 1993 | A |
5181512 | Viebach et al. | Jan 1993 | A |
5184605 | Grzeszykowski | Feb 1993 | A |
5186162 | Talish et al. | Feb 1993 | A |
5191880 | McLeod et al. | Mar 1993 | A |
5197475 | Antich et al. | Mar 1993 | A |
5201766 | Georgette | Apr 1993 | A |
5209221 | Riedlinger | May 1993 | A |
5211160 | Talish et al. | May 1993 | A |
5230334 | Klopotek | Jul 1993 | A |
5230345 | Curran et al. | Jul 1993 | A |
5230646 | Thorup | Jul 1993 | A |
5230921 | Waltonen et al. | Jul 1993 | A |
5235981 | Hascoet et al. | Aug 1993 | A |
5254123 | Bushey | Oct 1993 | A |
5259384 | Kaufman et al. | Nov 1993 | A |
5269306 | Warnking et al. | Dec 1993 | A |
5273028 | McLeod et al. | Dec 1993 | A |
5280728 | Sato et al. | Jan 1994 | A |
5284143 | Rattner | Feb 1994 | A |
5285788 | Arenson et al. | Feb 1994 | A |
5295931 | Dreibelbis et al. | Mar 1994 | A |
5301683 | Durkan | Apr 1994 | A |
5307284 | Brunfeldt et al. | Apr 1994 | A |
5309898 | Kaufman et al. | May 1994 | A |
5310408 | Schryver et al. | May 1994 | A |
5314401 | Tepper | May 1994 | A |
5316000 | Chapelon et al. | May 1994 | A |
5318561 | McLeod et al. | Jun 1994 | A |
5318779 | Hakamatsuka et al. | Jun 1994 | A |
5322067 | Prater et al. | Jun 1994 | A |
5323769 | Bommannan et al. | Jun 1994 | A |
5327890 | Matura et al. | Jul 1994 | A |
5330481 | Hood et al. | Jul 1994 | A |
5330489 | Green et al. | Jul 1994 | A |
5334214 | Putnam | Aug 1994 | A |
5339804 | Kemp | Aug 1994 | A |
5340510 | Bowen | Aug 1994 | A |
5351389 | Erickson et al. | Oct 1994 | A |
5363850 | Soni et al. | Nov 1994 | A |
5366465 | Mirza | Nov 1994 | A |
5367500 | Ng | Nov 1994 | A |
5368044 | Cain et al. | Nov 1994 | A |
5376065 | McLeod et al. | Dec 1994 | A |
5380269 | Urso | Jan 1995 | A |
5386830 | Powers et al. | Feb 1995 | A |
5393296 | Rattner | Feb 1995 | A |
5394877 | Orr et al. | Mar 1995 | A |
5394878 | Frazin et al. | Mar 1995 | A |
5398290 | Brethour | Mar 1995 | A |
5400795 | Murphy et al. | Mar 1995 | A |
5405389 | Conta et al. | Apr 1995 | A |
5409446 | Rattner | Apr 1995 | A |
RE34959 | Potts | May 1995 | E |
5413550 | Castel | May 1995 | A |
5415167 | Wilk | May 1995 | A |
5417215 | Evans et al. | May 1995 | A |
5424550 | Kawano et al. | Jun 1995 | A |
5425954 | Thompson et al. | Jun 1995 | A |
5431612 | Holden | Jul 1995 | A |
5434827 | Bolorforosh | Jul 1995 | A |
5441051 | Hileman et al. | Aug 1995 | A |
5441058 | Fareed | Aug 1995 | A |
5448994 | Iinuma | Sep 1995 | A |
5460595 | Hall et al. | Oct 1995 | A |
5466215 | Lair et al. | Nov 1995 | A |
5468220 | Sucher | Nov 1995 | A |
5476438 | Edrich et al. | Dec 1995 | A |
5478306 | Stoner | Dec 1995 | A |
5484388 | Bassett et al. | Jan 1996 | A |
5492525 | Gibney | Feb 1996 | A |
5495846 | Uehara et al. | Mar 1996 | A |
5496256 | Bock et al. | Mar 1996 | A |
5501657 | Feero | Mar 1996 | A |
5507800 | Strickland | Apr 1996 | A |
5507830 | DeMane et al. | Apr 1996 | A |
5509933 | Davidson et al. | Apr 1996 | A |
5520612 | Winder et al. | May 1996 | A |
5524624 | Tepper et al. | Jun 1996 | A |
5526815 | Granz et al. | Jun 1996 | A |
5541489 | Dunstan | Jul 1996 | A |
5547459 | Kaufman et al. | Aug 1996 | A |
5556372 | Talish et al. | Sep 1996 | A |
5578060 | Pohl et al. | Nov 1996 | A |
5615466 | Safari et al. | Apr 1997 | A |
5626554 | Ryaby et al. | May 1997 | A |
5626630 | Markowitz et al. | May 1997 | A |
5630837 | Crowley | May 1997 | A |
5644093 | Wright et al. | Jul 1997 | A |
5648941 | King | Jul 1997 | A |
5656016 | Ogden | Aug 1997 | A |
5665141 | Vago | Sep 1997 | A |
5680863 | Hossack et al. | Oct 1997 | A |
5690608 | Watanabe et al. | Nov 1997 | A |
5691960 | Gentilman et al. | Nov 1997 | A |
5699803 | Carodiskey | Dec 1997 | A |
5702353 | Guzzini et al. | Dec 1997 | A |
5702389 | Taylor et al. | Dec 1997 | A |
5706818 | Gondo | Jan 1998 | A |
5708236 | Shaanan et al. | Jan 1998 | A |
5721400 | Haraldsson et al. | Feb 1998 | A |
5725482 | Bishop | Mar 1998 | A |
5728095 | Taylor et al. | Mar 1998 | A |
5730705 | Talish et al. | Mar 1998 | A |
5738625 | Gluck | Apr 1998 | A |
5741317 | Ostrow | Apr 1998 | A |
5743862 | Izumi | Apr 1998 | A |
5752924 | Kaufman et al. | May 1998 | A |
5755746 | Lifshey et al. | May 1998 | A |
5762616 | Talish | Jun 1998 | A |
5779600 | Pape | Jul 1998 | A |
5785656 | Chiabrera et al. | Jul 1998 | A |
5818149 | Safari et al. | Oct 1998 | A |
5829437 | Bridges | Nov 1998 | A |
5843741 | Wong et al. | Dec 1998 | A |
5856622 | Yamamoto et al. | Jan 1999 | A |
5868649 | Erickson et al. | Feb 1999 | A |
5871446 | Wilk | Feb 1999 | A |
5886302 | Germanton et al. | Mar 1999 | A |
5891143 | Taylor et al. | Apr 1999 | A |
5899425 | Corey, Jr. et al. | May 1999 | A |
5904659 | Duarte et al. | May 1999 | A |
5906580 | Kline-Schoder et al. | May 1999 | A |
5954675 | Dellagatta | Sep 1999 | A |
5957814 | Eschenbach | Sep 1999 | A |
5962790 | Lynnworth et al. | Oct 1999 | A |
5971984 | Taylor et al. | Oct 1999 | A |
5984882 | Rosenshein et al. | Nov 1999 | A |
5997490 | McLeod et al. | Dec 1999 | A |
6019710 | Dalebout et al. | Feb 2000 | A |
6022349 | McLeod et al. | Feb 2000 | A |
6028066 | Unger | Feb 2000 | A |
6030386 | Taylor et al. | Feb 2000 | A |
6048323 | Hon | Apr 2000 | A |
6050943 | Slayton et al. | Apr 2000 | A |
6061597 | Rieman et al. | May 2000 | A |
6065350 | Hill et al. | May 2000 | A |
6068596 | Weth et al. | May 2000 | A |
6080088 | Petersen et al. | Jun 2000 | A |
6082181 | Greenwood | Jul 2000 | A |
6086078 | Ferez | Jul 2000 | A |
6088613 | Unger | Jul 2000 | A |
6093135 | Huang | Jul 2000 | A |
6105431 | Duffill et al. | Aug 2000 | A |
6113559 | Klopotek et al. | Sep 2000 | A |
6165144 | Talish et al. | Dec 2000 | A |
6179797 | Brotz | Jan 2001 | B1 |
6190336 | Duarte et al. | Feb 2001 | B1 |
6206843 | Iger et al. | Mar 2001 | B1 |
6213958 | Winder | Apr 2001 | B1 |
6234975 | McLeod et al. | May 2001 | B1 |
6234990 | Rowe et al. | May 2001 | B1 |
6251088 | Kaufman et al. | Jun 2001 | B1 |
6258020 | Lopez | Jul 2001 | B1 |
6261221 | Tepper et al. | Jul 2001 | B1 |
6261249 | Talish et al. | Jul 2001 | B1 |
6264650 | Hovda et al. | Jul 2001 | B1 |
6273864 | Duarte et al. | Aug 2001 | B1 |
6311402 | Brandl et al. | Nov 2001 | B1 |
6322527 | Talish | Nov 2001 | B1 |
6355006 | Ryaby et al. | Mar 2002 | B1 |
6360027 | Hossack et al. | Mar 2002 | B1 |
6394955 | Perlitz | May 2002 | B1 |
6397683 | Hagenmeyer et al. | Jun 2002 | B1 |
6406443 | Talish | Jun 2002 | B1 |
6436060 | Talish | Aug 2002 | B1 |
6443898 | Unger | Sep 2002 | B1 |
6464687 | Ishikawa et al. | Oct 2002 | B1 |
6503214 | Talish | Jan 2003 | B1 |
6524261 | Talish et al. | Feb 2003 | B2 |
6685656 | Duarte et al. | Feb 2004 | B1 |
6733468 | Talish | May 2004 | B2 |
6932308 | Talish et al. | Aug 2005 | B2 |
6960173 | Babaev | Nov 2005 | B2 |
7108663 | Talish | Sep 2006 | B2 |
7211060 | Talish | May 2007 | B1 |
20020016557 | Duarte | Feb 2002 | A1 |
20020068871 | Mendlein et al. | Jun 2002 | A1 |
20020103448 | Babaev | Aug 2002 | A1 |
20020115960 | Redding, Jr. | Aug 2002 | A1 |
20020156400 | Babaev | Oct 2002 | A1 |
20020190136 | Babaev | Dec 2002 | A1 |
20030013956 | Michaeli | Jan 2003 | A1 |
20030153848 | Talish | Aug 2003 | A1 |
20030153849 | Huckle | Aug 2003 | A1 |
20060106424 | Bachem | May 2006 | A1 |
Number | Date | Country |
---|---|---|
199950292 | Feb 2000 | AU |
1328485 | Apr 1994 | CA |
3639263 | Jun 1987 | DE |
19613425 | Jan 1997 | DE |
298 11 185 | Dec 1998 | DE |
41 11 055 | Oct 2001 | DE |
0 181 506 | May 1986 | EP |
0 331 348 | Sep 1989 | EP |
0 425 785 | May 1991 | EP |
0 536 875 | Apr 1993 | EP |
0 631 772 | Jan 1995 | EP |
0 679 371 | Nov 1995 | EP |
0 695 559 | Feb 1996 | EP |
0 965 839 | Dec 1999 | EP |
2156983 | Oct 1985 | GB |
2263406 | Jul 1993 | GB |
2277448 | Nov 1994 | GB |
2303552 | Feb 1997 | GB |
SHO 62-47359 | Mar 1987 | JP |
HEI 4-82567 | Mar 1992 | JP |
HEI 4-82568 | Mar 1992 | JP |
HEI 4-82569 | Mar 1992 | JP |
HEI 5-269159 | Oct 1993 | JP |
2000-167009 | Jun 2000 | JP |
WO 8503449 | Aug 1985 | WO |
WO 8800845 | Feb 1988 | WO |
WO 8802250 | Apr 1988 | WO |
WO 9006720 | Jun 1990 | WO |
WO 9413411 | Jun 1994 | WO |
WO 9503744 | Feb 1995 | WO |
WO 9533416 | Dec 1995 | WO |
WO 9625112 | Aug 1996 | WO |
WO 9625888 | Aug 1996 | WO |
WO 9733649 | Sep 1997 | WO |
WO 9810729 | Mar 1998 | WO |
WO9829036 | Jul 1998 | WO |
WO 9834578 | Aug 1998 | WO |
WO 9847570 | Oct 1998 | WO |
WO 9918876 | Apr 1999 | WO |
WO 9922652 | May 1999 | WO |
WO 9948621 | Sep 1999 | WO |
WO 9956829 | Nov 1999 | WO |
WO 9958080 | Nov 1999 | WO |
WO 0003663 | Jan 2000 | WO |
WO 0028925 | May 2000 | WO |
WO 0067846 | Nov 2000 | WO |
WO 0071207 | Nov 2000 | WO |
WO 0076406 | Dec 2000 | WO |
WO03090868 | Nov 2003 | WO |
WO2005007057 | Jan 2005 | WO |
Number | Date | Country | |
---|---|---|---|
20030153849 A1 | Aug 2003 | US |
Number | Date | Country | |
---|---|---|---|
60037367 | Feb 1997 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 09436999 | Nov 1999 | US |
Child | 10096216 | US | |
Parent | PCT/US98/02447 | Feb 1998 | US |
Child | 09436999 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 10096216 | Mar 2002 | US |
Child | 10131784 | US |